Drawing upon its drug discovery chemistry expertise, Tripos Discovery Research (TDR), which is based in Bude, England, has entered into an extension of its previous chemistry research contract with Servier to develop preclinical development candidates for obesity.
Employing its proprietary ChemSpace technology and knowledge-driven chemistry process, TDR will work to optimize Servier’s current lead series and develop backup candidates in parallel.
TDR will receive ongoing research fees from Servier and will also be awarded undisclosed preclinical milestone payments for drug candidates discovered during the collaboration.
“We are delighted with the success of our collaboration so far and look forward to continuing this fruitful relationship,” commented Dr Mark Allen, senior vice president and managing director of TDR. “We believe that by combining the complementary strengths of Tripos and Servier, we will be able to successfully discover promising new medicines in this important area.”